Investors wait on make or break date for QRxPharma

Jessica GardnerDeputy editor - News

Updated Mar 17, 2014 – 9.50am, first published at 12.22am

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Investors in pain management drug developer QRxPharma face a nervous wait until May for a decision from the US regulator that could make or break the company.

An application for the company’s Moxduo Immediate Release pain drug, which is a combination of morphine and oxycodone, will be either approved or rejected by May 25, ending a long and bumpy ride for investors in the biotechnology stock.